BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Liu D, Wang Z, Cai C, Jiang H, Yu G. Porphyran-derived oligosaccharides alleviate NAFLD and related cecal microbiota dysbiosis in mice. FASEB J 2021;35:e21458. [PMID: 33948987 DOI: 10.1096/fj.202000763RRR] [Reference Citation Analysis]
2 Singh SP, Anirvan P, Khandelwal R, Satapathy SK. Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille? J Clin Transl Hepatol 2021;9:931-8. [PMID: 34966656 DOI: 10.14218/JCTH.2021.00174] [Reference Citation Analysis]
3 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
4 Embade N, Mariño Z, Diercks T, Cano A, Lens S, Cabrera D, Navasa M, Falcón-Pérez JM, Caballería J, Castro A, Bosch J, Mato JM, Millet O. Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. PLoS One 2016;11:e0155094. [PMID: 27158896 DOI: 10.1371/journal.pone.0155094] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
5 Jain AK, Sharma A, Arora S, Blomenkamp K, Jun IC, Luong R, Westrich DJ, Mittal A, Buchanan PM, Guzman MA, Long J, Neuschwander-Tetri BA, Teckman J. Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition. JPEN J Parenter Enteral Nutr 2017;41:198-207. [PMID: 27503935 DOI: 10.1177/0148607116661838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
6 Vanhove AS, Hang S, Vijayakumar V, Wong AC, Asara JM, Watnick PI. Vibrio cholerae ensures function of host proteins required for virulence through consumption of luminal methionine sulfoxide. PLoS Pathog 2017;13:e1006428. [PMID: 28586382 DOI: 10.1371/journal.ppat.1006428] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
7 Rosas-Villegas A, Sánchez-Tapia M, Avila-Nava A, Ramírez V, Tovar AR, Torres N. Differential Effect of Sucrose and Fructose in Combination with a High Fat Diet on Intestinal Microbiota and Kidney Oxidative Stress. Nutrients 2017;9:E393. [PMID: 28420148 DOI: 10.3390/nu9040393] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
8 Fousekis FS, Mitselos IV, Christodoulou DK. New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature. Saudi J Gastroenterol 2021;27:3-12. [PMID: 33642350 DOI: 10.4103/sjg.sjg_551_20] [Reference Citation Analysis]
9 Yu Q, Jiang Z, Zhang L. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol Ther 2018;190:81-90. [PMID: 29684468 DOI: 10.1016/j.pharmthera.2018.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
10 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
11 Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
12 Birerdinc A, Younossi Z. Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease? Journal of Hepatology 2015;62:761-2. [DOI: 10.1016/j.jhep.2015.01.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
13 Seaman DR. Toxins, Toxicity, and Endotoxemia: A Historical and Clinical Perspective for Chiropractors. J Chiropr Humanit 2016;23:68-76. [PMID: 27920621 DOI: 10.1016/j.echu.2016.07.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Yu M, Zhu Y, Cong Q, Wu C. Metabonomics Research Progress on Liver Diseases. Can J Gastroenterol Hepatol 2017;2017:8467192. [PMID: 28321390 DOI: 10.1155/2017/8467192] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
15 Kirpich IA, Parajuli D, McClain CJ. Microbiome in NAFLD and ALD. Clin Liver Dis (Hoboken) 2015;6:55-8. [PMID: 26576267 DOI: 10.1002/cld.494] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
16 Heizati M, Li N, Shao L, Yao X, Wang Y, Hong J, Zhou L, Zhang D, Chang G, Abulikemu S. Does increased serum d-lactate mean subclinical hyperpermeability of intestinal barrier in middle-aged nonobese males with OSA? Medicine (Baltimore) 2017;96:e9144. [PMID: 29245360 DOI: 10.1097/MD.0000000000009144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Cortez-Pinto H, Borralho P, Machado J, Lopes MT, Gato IV, Santos AM, Guerreiro AS. Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). GE Port J Gastroenterol 2016;23:132-41. [PMID: 28868449 DOI: 10.1016/j.jpge.2016.01.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
18 Zhao M, Qian D, Shang E, Liu P, Jiang S, Guo J, Su S, Duan J, Du L, Tao J. Metabolites of Rehmannia glutinosa Libosch extract by intestinal bacteria from normal and chronic kidney disease rats in vitro. Anal Methods 2015;7:5325-33. [DOI: 10.1039/c5ay01257k] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Xia F, Zhou BJ. Role of gut-liver axis dysfunction in pathogenesis of non-alcoholic fatty liver disease: Implications for treatment strategies. Shijie Huaren Xiaohua Zazhi 2018; 26(24): 1439-1447 [DOI: 10.11569/wcjd.v26.i24.1439] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Akhtar DH, Iqbal U, Vazquez-Montesino LM, Dennis BB, Ahmed A. Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2019;7:362-370. [PMID: 31915606 DOI: 10.14218/jcth.2019.00028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Kumar JA, Teckman JH. Controversies in the Mechanism of Total Parenteral Nutrition Induced Pathology. Children (Basel) 2015;2:358-70. [PMID: 27417369 DOI: 10.3390/children2030358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
22 Joshi-Barve S, Kirpich I, Cave MC, Marsano LS, McClain CJ. Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences. Cell Mol Gastroenterol Hepatol 2015;1:356-67. [PMID: 28210688 DOI: 10.1016/j.jcmgh.2015.05.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
23 Ishioka M, Miura K, Minami S, Shimura Y, Ohnishi H. Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models. Dig Dis Sci. 2017;62:396-406. [PMID: 27913996 DOI: 10.1007/s10620-016-4393-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
24 Liu Q, Liu S, Chen L, Zhao Z, Du S, Dong Q, Xin Y, Xuan S. Role and effective therapeutic target of gut microbiota in NAFLD/NASH. Exp Ther Med 2019;18:1935-44. [PMID: 31410156 DOI: 10.3892/etm.2019.7781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 de Castro CA, dos Santos Dias MM, da Silva KA, dos Reis SA, da Conceição LL, De Nadai Marcon L, de Sousa Moraes LF, do Carmo Gouveia Peluzio M. Liver Biomarkers and Their Applications to Nutritional Interventions in Animal Studies. In: Patel VB, Preedy VR, editors. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands; 2017. pp. 129-52. [DOI: 10.1007/978-94-007-7675-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192-202. [PMID: 25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001] [Cited by in Crossref: 175] [Cited by in F6Publishing: 164] [Article Influence: 25.0] [Reference Citation Analysis]
27 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 16.0] [Reference Citation Analysis]
28 O'Brien P, Han G, Ganpathy P, Pitre S, Zhang Y, Ryan J, Sim PY, Harding SV, Gray R, Preedy VR, Sanders TAB, Corpe CP. Chronic Effects of a High Sucrose Diet on Murine Gastrointestinal Nutrient Sensor Gene and Protein Expression Levels and Lipid Metabolism. Int J Mol Sci 2020;22:E137. [PMID: 33375525 DOI: 10.3390/ijms22010137] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Gholizadeh P, Mahallei M, Pormohammad A, Varshochi M, Ganbarov K, Zeinalzadeh E, Yousefi B, Bastami M, Tanomand A, Mahmood SS, Yousefi M, Asgharzadeh M, Kafil HS. Microbial balance in the intestinal microbiota and its association with diabetes, obesity and allergic disease. Microb Pathog. 2019;127:48-55. [PMID: 30503960 DOI: 10.1016/j.micpath.2018.11.031] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
30 Chen KL, Madak-erdogan Z. Estrogens and female liver health. Steroids 2018;133:38-43. [DOI: 10.1016/j.steroids.2017.10.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
31 Deng Z, Li Z, Sun C, Xie H, Chen Z, Liu J, Wang H, Zhang C, Wang G. The association between inflammation, the microbiome and urethane-induced pulmonary adenocarcinoma. Oncol Lett 2018;15:6352-60. [PMID: 29725395 DOI: 10.3892/ol.2018.8167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73:1969-1987. [PMID: 26894897 DOI: 10.1007/s00018-016-2161-x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 15.2] [Reference Citation Analysis]
33 Wang Q, Wang B, Saxena V, Miles L, Tiao J, Mortensen JE, Nathan JD. The gut-liver axis: impact of a mouse model of small-bowel bacterial overgrowth. J Surg Res 2018;221:246-56. [PMID: 29229136 DOI: 10.1016/j.jss.2017.08.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
34 Castillo V, Figueroa F, González-Pizarro K, Jopia P, Ibacache-Quiroga C. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods 2021;10:1719. [PMID: 34441497 DOI: 10.3390/foods10081719] [Reference Citation Analysis]
35 Mikolasevic I, Delija B, Mijic A, Stevanovic T, Skenderevic N, Sosa I, Krznaric-Zrnic I, Abram M, Krznaric Z, Domislovic V, Filipec Kanizaj T, Radic-Kristo D, Cubranic A, Grubesic A, Nakov R, Skrobonja I, Stimac D, Hauser G. Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. Int J Clin Pract 2021;75:e13947. [PMID: 33406286 DOI: 10.1111/ijcp.13947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Yan LH, Mu B, Pan D, Shi YN, Yuan JH, Guan Y, Li W, Zhu XY, Guo L. Association between small intestinal bacterial overgrowth and beta-cell function of type 2 diabetes. J Int Med Res 2020;48:300060520937866. [PMID: 32691685 DOI: 10.1177/0300060520937866] [Reference Citation Analysis]
37 Boursier J, Diehl AM. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clin Liver Dis 2016;20:263-75. [PMID: 27063268 DOI: 10.1016/j.cld.2015.10.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
38 Kuang L, Zhou W, Jiang Y. Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis. PLoS One 2021;16:e0260479. [PMID: 34855819 DOI: 10.1371/journal.pone.0260479] [Reference Citation Analysis]
39 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
41 Villard A, Boursier J, Andriantsitohaina R. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis? Am J Physiol Gastrointest Liver Physiol 2021;320:G485-95. [PMID: 33471632 DOI: 10.1152/ajpgi.00362.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wei W, Sun W, Yu S, Yang Y, Ai L. Butyrate production from high-fiber diet protects against lymphoma tumor. Leukemia & Lymphoma 2016;57:2401-8. [DOI: 10.3109/10428194.2016.1144879] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
43 Zhang ZL, Duan ZJ. Gut-liver axis: An important target for prevention and treatment of liver diseases. Shijie Huaren Xiaohua Zazhi 2016; 24(23): 3454-3460 [DOI: 10.11569/wcjd.v24.i23.3454] [Reference Citation Analysis]
44 Flisiak-Jackiewicz M, Bobrus-Chociej A, Tarasów E, Wojtkowska M, Białokoz-Kalinowska I, Lebensztejn DM. Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children. Can J Gastroenterol Hepatol 2018;2018:3870454. [PMID: 29854715 DOI: 10.1155/2018/3870454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
45 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
46 Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol. 2019;5:1-10. [PMID: 30915401 DOI: 10.5114/ceh.2019.83151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
47 Ierardi E, Losurdo G, Sorrentino C, Giorgio F, Rossi G, Marinaro A, Romagno KR, Di Leo A, Principi M. Macronutrient intakes in obese subjects with or without small intestinal bacterial overgrowth: an alimentary survey. Scand J Gastroenterol. 2016;51:277-280. [PMID: 26375876 DOI: 10.3109/00365521.2015.1086020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
48 Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem. 2015;48:923-930. [PMID: 26151226 DOI: 10.1016/j.clinbiochem.2015.06.023] [Cited by in Crossref: 128] [Cited by in F6Publishing: 132] [Article Influence: 18.3] [Reference Citation Analysis]
49 Konrad P, Chojnacki J, Gąsiorowska A, Rudnicki C, Kaczka A, Chojnacki C. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol 2018;13:213-7. [PMID: 30302165 DOI: 10.5114/pg.2018.74228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Elaine Chen YF, Lai MW, Tsai CN, Lai JY, Yang YC, Chen SY. Association of gut microbiota composition and copy number variation with Kasai procedure outcomes in infants with biliary atresia. Pediatr Neonatol 2020;61:238-40. [PMID: 32098726 DOI: 10.1016/j.pedneo.2019.12.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Jain AK, le Roux CW, Puri P, Tavakkoli A, Gletsu-Miller N, Laferrère B, Kellermayer R, DiBaise JK, Martindale RG, Wolfe BM. Proceedings of the 2017 ASPEN Research Workshop-Gastric Bypass: Role of the Gut. JPEN J Parenter Enteral Nutr 2018;42:279-95. [PMID: 29443403 DOI: 10.1002/jpen.1121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]